Escitalopram-associated rhabdomyolysis

Area of Science:

• Pharmacology
• Neurology
• Toxicology

Background:

• Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed for depression and anxiety disorders.
• Escitalopram is a commonly used SSRI known for its efficacy and generally favorable safety profile.
• Adverse drug reactions, though uncommon, necessitate ongoing surveillance and reporting.

Observation:

• A case history involving a patient who developed rhabdomyolysis is presented.
• The condition occurred during monotherapy with escitalopram at a standard therapeutic dosage.
• Rhabdomyolysis involves the breakdown of muscle tissue, leading to the release of muscle components into the bloodstream.

Findings:

• This case suggests a potential causal link between escitalopram monotherapy and the development of rhabdomyolysis.
• The occurrence at a recommended dose indicates that this side effect may not be strictly dose-dependent.
• Rhabdomyolysis is identified as a rare and previously underreported adverse effect associated with SSRIs.

Implications:

• Clinicians should be aware of this rare adverse effect when prescribing escitalopram, even as monotherapy.
• Enhanced vigilance for muscle-related symptoms in patients on SSRIs may be warranted.
• Further research is needed to elucidate the mechanism and incidence of SSRI-induced rhabdomyolysis.